Ivan Kairatov is a seasoned biopharma expert with a distinguished background in research and development, focusing specifically on the intersection of immunology and biotechnology. With years of experience analyzing the clinical and commercial trajectories of next-generation therapies, he has become a leading voice in understanding how molecular precision translates into patient outcomes. In this discussion, we explore the evolving treatment landscape for psoriatic arthritis, specifically focusing on how new data comparing IL-17 blockers to IL-23 inhibitors is reshaping clinical expectations and the competitive dynamics of the pharmaceutical market.
How does blocking both the A and F subtypes of the IL-17 protein change the treatment landscape compared to traditional IL-23 inhibitors, and what specific physiological responses should clinicians look for when evaluating patients with joint-dominant disease?
The introduction of dual inhibition targeting both the IL-17A and IL-17F subtypes represents a significant shift in how we manage the inflammatory cascade in psoriatic arthritis. While traditional IL-23 inhibitors like Skyrizi are powerhouse treatments, they operate further upstream, whereas blocking both IL-17 subtypes provides a more direct and potent suppression of the cytokines responsible for joint inflammation. In clinical practice, this translates to a much faster impact on the synovial tissue; clinicians should specifically look for a rapid reduction in dactylitis and enthesitis, which often cause the most physical distress in joint-dominant patients. By neutralizing both isoforms, we are seeing a deeper level of molecular control that traditional single-target biologics sometimes struggle to reach in the early months of therapy.
When a therapy achieves a 50% improvement in tender and swollen joints within a 16-week window, how do you interpret that speed of response for a patient’s quality of life, and what clinical benchmarks are most critical when determining if a switch in biologic therapy is necessary?
Reaching the ACR50 benchmark within just 16 weeks is a profound milestone for a patient who has likely spent years struggling with chronic pain and limited mobility. This 50% reduction in tender and swollen joints often means the difference between a patient being able to return to work or remain on disability, providing a psychological boost that is just as vital as the physical recovery. When I evaluate the necessity of a switch, I look for a failure to meet these early markers; if we don’t see significant movement by that four-month window, the likelihood of long-term success diminishes. The speed of Bimzelx in the BE BOLD trial suggests that we are moving toward an era where “waiting and seeing” for six months to a year is no longer an acceptable clinical standard.
Even when clinical data demonstrates clear superiority in head-to-head trials, what logistical or commercial barriers usually prevent a rapid shift in drug adoption across the industry, and how do you navigate these challenges when managing complex, long-term patient care plans?
Data is often the loudest voice in the room, but it frequently runs into the wall of market access and established payer preferences. Even with head-to-head superiority, many healthcare systems and insurance providers have “step-therapy” protocols that require patients to fail on older, often cheaper, IL-23 or TNF inhibitors before they can access a newer drug like Bimzelx. Furthermore, companies like AbbVie have incredibly robust commercial infrastructures and long-standing relationships with providers that make their franchises very defensible despite new competition. Navigating this requires a patient-centric approach where we meticulously document the severity of joint involvement to justify the medical necessity of a dual IL-17A/F blocker right from the start.
Given that some newer therapies target specific protein subtypes while others focus on broader inflammatory pathways, how do you differentiate between dual-subtype blockers and established treatments in daily practice, and what specific patient symptoms indicate a need for this more precise targeting?
The differentiation really comes down to the “joint-first” versus “skin-first” presentation of the disease. In my experience, while IL-23 inhibitors are exceptionally strong for clearing plaque psoriasis, the dual-subtype IL-17 blockers show a particular edge in patients whose primary complaint is the structural and mechanical pain of the joints. If a patient presents with “sausage digits” or severe morning stiffness that lasts for hours, that is a clear signal that the underlying IL-17 biology is driving the pathology more aggressively. We use this precision targeting to match the drug to the patient’s dominant symptom profile, ensuring we aren’t just treating the skin while the joints continue to erode.
What is your forecast for the competition between IL-17 and IL-23 inhibitors in the psoriatic arthritis market?
The market is currently at a fascinating crossroads where clinical superiority is meeting commercial reality, and I expect to see a bifurcated landscape where IL-17 inhibitors regain significant ground in rheumatology clinics. While Bimzelx saw its sales quadruple to roughly $2.5 billion last year, it still faces an uphill battle against the entrenched market share of established players, but the BE BOLD data provides the clinical ammunition needed to challenge that status quo. My forecast is that we will see a shift where IL-17 dual-blockers become the preferred first-line biologic for joint-dominant psoriatic arthritis, while IL-23s maintain their dominance in dermatology-led cases. Ultimately, the next three years will be defined by how well these companies can translate trial data into favorable positions on insurance formularies to ensure patients actually get the “superior” treatment they were promised in the studies.
